Veracyte, Inc.
Veracyte, Inc.
Explore linked clinical trials.8 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Not applicable | 2026-09-09 | NCT04396808 | |
| Decipher Genomics Resource for Intelligent Discovery | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, kidney cancer, kidney disorder, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Enrolling by invitation | Not stated | 2026-08-18 | NCT02609269 | |
| Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 2 / Phase 3 | 2026-03-19 | NCT06282588 | |
| Image-guided, Tumor-focused Radiotherapy Treatment in Intermediate and High-risk Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 2 | 2026-02-17 | NCT06990542 | |
| Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not applicable | 2026-01-30 | NCT03769415 | |
| Focal or Radical Therapy: a Lesion-based Molecular Evaluation in Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Not applicable | 2026-01-08 | NCT07282808 | |
| tislelizUMaB in canceR Patients With molEcuLar residuaL Disease | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Thoracic Neoplasms, cancer, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, intestinal disorder, lung cancer, lung disorder, lung neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, respiratory system disorder, respiratory tract neoplasm, sarcoma | Recruiting | Phase 3 | 2025-05-13 | NCT06332274 | |
| Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier | Neoplasms by Site, Thoracic Neoplasms, lung cancer, lung disorder, lung neoplasm, neoplasm, pulmonary coin lesion, respiratory system disorder, respiratory tract neoplasm | Recruiting | Not stated | 2024-11-13 | NCT06426628 |